The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. (2016)

First Author: Von Delft A
Attributed to:  Immunity in the face of diversity and the development of novel potent HCV vaccines funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/gutjnl-2014-308724

PubMed Identifier: 26092843

Publication URI: http://europepmc.org/abstract/MED/26092843

Type: Journal Article/Review

Volume: 65

Parent Publication: Gut

Issue: 1

ISSN: 0017-5749